OAS1 antibody (AA 296-395)

Catalog No. ABIN7142170

Product Details anti-OAS1 Antibody

Target: OAS1 (2',5'-Oligoadenylate Synthetase 1, 40/46kDa (OAS1))

Binding Specificity: AA 296-395

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This OAS1 antibody is un-conjugated

Application: Immunohistochemistry (IHC), ELISA

Cross-Reactivity: Human

Purification: >95%, Protein G purified

Immunogen: Recombinant Human 2\'-5\'-oligoadenylate synthase 1 protein (296-395AA)

Isotype: IgG

Application Details

Application Notes: Recommended dilution: IHC:1:20-1:200,

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for OAS1

Target: OAS1 (2',5'-Oligoadenylate Synthetase 1, 40/46kDa (OAS1))

Alternative Name: OAS1 (OAS1 Products)

Synonyms: OAS1 antibody, IFI-4 antibody, OIAS antibody, OIASI antibody, L3 antibody, Pp2a2 antibody, 2',5'-oligoadenylate synthetase 1 antibody, 2'-5'-oligoadenylate synthetase 1 antibody, 2'-5' oligoadenylate synthetase 1A antibody, protein phosphatase 2 catalytic subunit beta antibody, OAS1 antibody, Oas1a antibody, Ppp2cb antibody, Oas1 antibody

Background:

Background: Interferon-induced, dsRNA-activated antiviral enzyme which plays a critical role in cellular innate antiviral response. In addition, it may also play a role in other cellular processes such as apoptosis, cell growth, differentiation and gene regulation. Synthesizes higher oligomers of 2\'-5\'-oligoadenylates (2-5A) from ATP which then bind to the inactive monomeric form of ribonuclease L (RNase L) leading to its dimerization and subsequent activation. Activation of RNase L leads to degradation of cellular as well as viral RNA, resulting in the inhibition of protein synthesis, thus terminating viral replication. Can mediate the antiviral effect via the classical RNase L-dependent pathway or an alternative antiviral pathway independent of RNase L. The secreted form displays antiviral effect against vesicular stomatitis virus (VSV), herpes simplex virus type 2 (HSV-2), and encephalomyocarditis virus (EMCV) and stimulates the alternative antiviral pathway independent of RNase L.

Aliases: (2 5')oligo(A) synthetase 1 antibody, (2-5'')oligo(A) synthase 1 antibody, 2 5 Oligoadenylate Synthetase 1 antibody, 2 5' oligo A synthase 1 antibody, 2 5' oligo A synthetase 1 antibody, 2 5A synthase 1 antibody, 2 5A synthetase 1 antibody, 2' 5' oligo A synthetase 1 antibody, 2' 5' oligoadenylate synthetase 1 40/46 kDa antibody, 2' 5' oligoadenylate synthetase 1 antibody, 2' 5' oligoisoadenylate synthetase 1 antibody, 2''-5''-oligoadenylate synthase 1 antibody, 2'5' oligo A synthetase 1 antibody, 2'5' oligoadenylate synthetase 1 antibody, 2'5' oligoisoadenylate synthetase 1 antibody, 2-5A synthase 1 antibody, E18/E16 antibody, IFI 4 antibody, IFI4 antibody, OAS 1 antibody, OAS1 antibody, OAS1_HUMAN antibody, OIAS antibody, OIASI antibody, p46/p42 OAS antibody

UniProt: P00973

Pathways: Hepatitis C